Jacques Troncy

2.4k total citations
34 papers, 1.0k citations indexed

About

Jacques Troncy is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jacques Troncy has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 13 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Jacques Troncy's work include Acute Myeloid Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (6 papers) and Neutropenia and Cancer Infections (5 papers). Jacques Troncy is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (6 papers) and Neutropenia and Cancer Infections (5 papers). Jacques Troncy collaborates with scholars based in France, United States and Italy. Jacques Troncy's co-authors include D Fière, E Archimbaud, Denis Guyotat, D. Treille, T Tsuruo, P Calmard-Oriol, Lydia Campos, Michel Attal, Jean‐Gabriel Fuzibet and Xavier Leleu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Obstetrics and Gynecology.

In The Last Decade

Jacques Troncy

34 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacques Troncy France 12 669 528 504 173 171 34 1.0k
T.J.M. de Witte Netherlands 18 766 1.1× 242 0.5× 352 0.7× 304 1.8× 161 0.9× 29 1.1k
R Leblay France 9 229 0.3× 294 0.6× 269 0.5× 380 2.2× 161 0.9× 31 832
JE Karp United States 12 335 0.5× 315 0.6× 290 0.6× 64 0.4× 174 1.0× 21 693
Jean‐Baptiste Micol France 18 726 1.1× 140 0.3× 452 0.9× 306 1.8× 144 0.8× 59 1.1k
Mette Østergaard Denmark 14 416 0.6× 163 0.3× 384 0.8× 112 0.6× 241 1.4× 29 843
Valérie Mialou France 12 407 0.6× 191 0.4× 228 0.5× 113 0.7× 109 0.6× 45 912
Jan Maxwell Nørgaard Denmark 17 724 1.1× 223 0.4× 340 0.7× 229 1.3× 298 1.7× 48 922
M Dardenne Netherlands 14 554 0.8× 216 0.4× 231 0.5× 106 0.6× 225 1.3× 26 963
Sudha Sazawal India 12 309 0.5× 94 0.2× 366 0.7× 160 0.9× 191 1.1× 55 811
Abraham S. Kanate United States 17 371 0.6× 376 0.7× 92 0.2× 129 0.7× 103 0.6× 61 815

Countries citing papers authored by Jacques Troncy

Since Specialization
Citations

This map shows the geographic impact of Jacques Troncy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Troncy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Troncy more than expected).

Fields of papers citing papers by Jacques Troncy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Troncy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Troncy. The network helps show where Jacques Troncy may publish in the future.

Co-authorship network of co-authors of Jacques Troncy

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Troncy. A scholar is included among the top collaborators of Jacques Troncy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Troncy. Jacques Troncy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haenni, Marisa, Pierre Châtre, Antoine Drapeau, et al.. (2024). Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France. Journal of Antimicrobial Chemotherapy. 80(2). 567–575. 1 indexed citations
2.
3.
Dumontet, Charles, Stefano Landi, Tony Reiman, et al.. (2009). Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplantation. 45(8). 1316–1324. 36 indexed citations
4.
Thomas, Xavier, Youcef Chelghoum, Fiorenza Barraco, & Jacques Troncy. (2009). The rationale and use of hypomethylation agents in adult acute myeloid leukemia. Expert Opinion on Drug Discovery. 4(2). 195–205. 1 indexed citations
5.
Thomas, Xavier & Jacques Troncy. (2009). Arsenic: a beneficial therapeutic poison - a historical overview.. PubMed. 35(1). 3–13. 14 indexed citations
6.
7.
Le, Quoc‐Hung, Youcef Chelghoum, Mohamed Elhamri, et al.. (2008). Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience. 2(3). 198–204. 9 indexed citations
8.
Le, Quoc‐Hung, Youcef Chelghoum, Mohamed Elhamri, et al.. (2007). Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience.. Blood. 110(11). 4352–4352. 2 indexed citations
9.
Moncharmont, P., Jacques Troncy, & D. Rigal. (2007). IgA anti-red blood cell auto-antibodies in Evans syndrome. Hematology. 12(6). 587–589. 3 indexed citations
10.
Thomas, Xavier, Quoc‐Hung Le, Emmanuelle Tavernier, et al.. (2005). Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).. Blood. 106(11). 4598–4598. 2 indexed citations
11.
Thomas, X., Q.H. Le, Stéphane de Botton, et al.. (2005). Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. Leukemia & lymphoma. 46(7). 1007–1016. 4 indexed citations
12.
13.
Belhabri, Amine, Xavier Thomas, Jacques Troncy, et al.. (1999). Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study. Leukemia & lymphoma. 36(1-2). 45–55. 5 indexed citations
14.
Thomas, X., Jacques Troncy, David Assouline, et al.. (1997). Serum Interleukin-6 Levels in Adult Acute Myelogenous Leukemia: Relationship with Disease Characteristics and Outcome. Leukemia & lymphoma. 24(3-4). 291–300. 13 indexed citations
15.
Troncy, Jacques, et al.. (1996). [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].. PubMed. 44(4). 299–305. 2 indexed citations
16.
Archimbaud, E, Xavier Thomas, M Michallet, et al.. (1994). Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia.. Journal of Clinical Oncology. 12(2). 262–267. 37 indexed citations
17.
Reiffers, Josy, J Cahn, Marion Montastruc, et al.. (1993). Peripheral blood stem cell transplantation followed by recombinant alpha interferon for chronic myelogenous leukemia in chronic phase: Preliminary results. Stem Cells. 11(S3). 23–24. 6 indexed citations
18.
Montastruc, Marion, J Cahn, G Souillet, et al.. (1993). Autologous blood stem-cell transplantation and recombinant interferon alfa in chronic myeloid leukemia.. PubMed. 30(3 Suppl 3). 51–2. 5 indexed citations
19.
Campos, Lydia, Denis Guyotat, E Archimbaud, et al.. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]. Blood. 79(2). 473–476. 426 indexed citations
20.
Archimbaud, E, Jacques Troncy, Catherine Sebban, et al.. (1989). Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology. 25(3). 223–225. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.J.M. de Witte Breakdown of academic impact, for papers by R Leblay Breakdown of academic impact, for papers by JE Karp Breakdown of academic impact, for papers by Jean‐Baptiste Micol Breakdown of academic impact, for papers by Mette Østergaard Breakdown of academic impact, for papers by Valérie Mialou Breakdown of academic impact, for papers by Jan Maxwell Nørgaard Breakdown of academic impact, for papers by M Dardenne Breakdown of academic impact, for papers by Sudha Sazawal Breakdown of academic impact, for papers by Abraham S. Kanate
Rankless by CCL
2026